Clinical Trial

Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial

Study acronym: HPVsign
Recruiting
View on ClinicalTrials.gov →
Summary
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-25; most recent amendment 2025-11-27.
Status change: Not Yet Recruiting → Recruiting 2025-11-27
Trial Details
NCT Number NCT06522256
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: INSERM SC10-US19
Conditions HPV Infection, Anal Cancer
Enrollment 100 participants
Start Date 2025-03-20
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-04